Archive · 3 Sep 2025
Piramal Pharma Shares Surge on JM Financial's Buy Rating
Imagine a company called Piramal Pharma, which makes medicines.
Their stock went up because a financial company thinks they are doing well.
Piramal is investing money to make a new medicine in the US with another company.
This new medicine helps people with heart problems.
The new medicine will likely bring in a lot of money.
The financial company expects Piramal to make more money in the next few years because of this new medicine and the recent investment.
They predict the stock price will rise to Rs 313 by June 2026, signaling positive growth.
Piramal Pharma shares increased by 8% on Wednesday.
JM Financial recommends a 'Buy' rating and raised earnings estimates.
Investment in US facility for FDC drug production.
The FDC drug combines Obicetrapib and Ezetimibe, targeting cardiovascular issues.
JM Financial forecasts increased revenue and EBITDA for Piramal Pharma.
- Who
- Piramal Pharma and NewAmsterdam Pharma
- What
- Piramal Pharma stock rose after JM Financial suggested a buy rating and announced a multimillion-dollar investment in a US facility.
- When
- Wednesday
- Where
- Sellersville, Pennsylvania (US) and India
- Why
- Investment expected to improve profitability through collaboration on fixed dose combination (FDC) drug production.
- Stock Movement
- Rose 8% on Wednesday
- Target Price
- Rs 313 (June 2026)
- Analyst Rating
- JM Financial: Buy
- Investment
- Multi-million dollar in US facility
- Drug Combination
- Obicetrapib and Ezetimibe (FDC)
- Revenue Forecast (FY27/FY28)
- Additional Rs 260cr/Rs 510cr